Details for the presentation are as follows:
Poster Presentation: A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti-CLDN18.2 Monoclonal Antibody, as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors (Abstract #391, Poster #G13)
Presenter:
Session Title: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
About AB011
AB011 is a humanized Claudin18.2 monoclonal antibody (mAb) product that has received an investigational new drug (IND) approval from the
About
CARsgen is a biopharmaceutical company with operations in
Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on
Cautionary Language Regarding Forward-Looking Statements
All statements in this announcement that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Company's current views, projections, beliefs and expectations with respect to future events as of the date of this announcement. Such forward-looking statements are based on a number of assumptions and factors beyond the Company's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this announcement might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading 'Principal Risks and Uncertainties' in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this announcement.
Contact:
WEB: https://www.carsgen.com
(C) 2023 Electronic News Publishing, source